Moberg Pharma AB (publ)
STO:MOB
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9.645
38.92
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Moberg Pharma AB (publ)
Moberg Pharma AB (publ)
Cash Equivalents
Moberg Pharma AB (publ)
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Moberg Pharma AB (publ)
STO:MOB
|
Cash Equivalents
kr60.6m
|
CAGR 3-Years
46%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Calliditas Therapeutics AB
STO:CALTX
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Camurus AB
STO:CAMX
|
Cash Equivalents
kr2.8B
|
CAGR 3-Years
86%
|
CAGR 5-Years
70%
|
CAGR 10-Years
N/A
|
|
|
S
|
Swedencare AB (publ)
STO:SECARE
|
Cash Equivalents
kr170m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
IRLAB Therapeutics AB
STO:IRLAB A
|
Cash Equivalents
kr111.3m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
I
|
InDex Pharmaceuticals Holding AB
STO:FLERIE
|
Cash Equivalents
kr911.3m
|
CAGR 3-Years
25%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
Moberg Pharma AB (publ)
Glance View
Moberg Pharma AB is a pharmaceutical company, which engages in the development and commercialization of medical products. The company is headquartered in Bromma, Stockholm. The company went IPO on 2011-05-26. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The firm collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. The company is active in more than 35 countries, and operates, among others, through Alterna LLC. The company also owns three Over-The-Counter (OTC) brands in the United States.
See Also
What is Moberg Pharma AB (publ)'s Cash Equivalents?
Cash Equivalents
60.6m
SEK
Based on the financial report for Dec 31, 2023, Moberg Pharma AB (publ)'s Cash Equivalents amounts to 60.6m SEK.
What is Moberg Pharma AB (publ)'s Cash Equivalents growth rate?
Cash Equivalents CAGR 3Y
46%
Over the last year, the Cash Equivalents growth was -52%. The average annual Cash Equivalents growth rates for Moberg Pharma AB (publ) have been 46% over the past three years .
You don't have any saved screeners yet
